A Measles Drug with Strong Activity without Toxicity Can Be Available Now for Emergency Use, Says NanoViricides - NV-387 Broad-Spectrum Antiviral with Activity Against Measles Virus

Core Insights - NanoViricides, Inc. announced that its clinical lead drug NV-387 has demonstrated strong efficacy against the Measles virus in a humanized animal model [1] - The company is preparing to make NV-387 available for emergency use application in response to ongoing Measles outbreaks [1] Company Summary - NanoViricides, Inc. is a publicly traded company listed on NYSE American under the ticker NNVC [1] - The company focuses on developing antiviral therapies, with NV-387 being a significant advancement in its pipeline [1] Industry Context - The announcement comes amid a rising number of Measles outbreaks, highlighting the urgent need for effective treatments [1] - The potential emergency use of NV-387 could position the company as a key player in addressing public health challenges related to viral infections [1]